GenowaySTU:JEH +5.88%62 EBITDA Margin % is 27.89% as of Dec. 2025, which is 56% above its 10-year median of 17.93. GuruFocus rates STU:JEH with a GF Score™ of 62/100 and a GF Value™ of €2.77 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 942 Biotechnology companies, Genoway ranks better than 85.77% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Genoway's EBITDA for the
six
months ended in Dec. 2025 was €3.17 Mil. Genoway's Revenue for the
six
months ended in Dec. 2025 was €11.35 Mil. Therefore, Genoway's EBITDA margin for the quarter that ended in Dec. 2025 was 27.89%.
Genoway (STU:JEH) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Genoway EBITDA Margin % Related Terms
Genoway EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Genoway's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:JEH vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Genoway's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genoway EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genoway's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Genoway's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genoway (STU:JEH) has a EBITDA Margin % of 27.89% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Genoway and its competitors. This is 56% above median its historical median of 17.93. Over the past decade, Genoway's EBITDA Margin % has ranged from 6.43 to 31.70. According to the industry distribution chart, Genoway ranks #134 out of 942 companies in the Biotechnology industry, placing it in the top 14.2%.
Is Genoway's EBITDA Margin % too high?
Genoway's current EBITDA Margin % of 27.89% is 56% above median its 10-year median of 17.93. Over the past 10 years, this metric has ranged from a low of 6.43 to a high of 31.70. Based on the distribution chart, Genoway ranks #134 out of 942 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Genoway has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genoway's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genoway ranks #134 out of 942 companies for EBITDA Margin %. This places Genoway in the top 14% of its industry — outperforming the majority of peers. Historically, Genoway's own EBITDA Margin % has ranged from 6.43 to 31.70 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Genoway and its competitors. Genoway's current EBITDA Margin % is 27.89%, which is 56% above median its own 10-year median of 17.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genoway stock overvalued right now?
Based on GuruFocus' analysis, Genoway (STU:JEH) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.77, compared to a current price of €2.34 — trading 15.5% below its estimated fair value. The current EBITDA Margin % is 27.89%, which is 56% above median its 10-year median of 17.93. Genoway's overall GF Score™ is 62/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Genoway (STU:JEH), the current EBITDA Margin % is 27.89% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genoway (STU:JEH) Overvalued in 2026?
Based on GuruFocus' analysis, Genoway stock appears to be undervalued.
The current stock price of €2.34 is trading 15.5% below its estimated GF Value™ of €2.77.
GuruFocus considers Genoway to be Modestly Undervalued.
Key valuation signals for STU:JEH:
EBITDA Margin %: 27.89% (56% above median its 10-year median of 17.93)
GF Value™: €2.77 vs. price of €2.34 (15.5% below fair value)
No single metric tells the full story. See the STU:JEH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genoway SA specializes in genetic designs to serve genetically modified (GM) mice, rat and cell lines for the biopharmaceutical industries and research industries.
62GF Score
Get the complete analysis for STU:JEH
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:JEH has been successfully added to your 
